Journal
NEURAL PLASTICITY
Volume 2019, Issue -, Pages -Publisher
HINDAWI LTD
DOI: 10.1155/2019/4209475
Keywords
-
Categories
Funding
- National Science Centre [2015/17/B/NZ3/03734]
Ask authors/readers for more resources
In neurons, Glycogen Synthase Kinase-3 (GSK-3) has been shown to regulate various critical processes underlying structural and functional synaptic plasticity. Mouse models with neuron-selective expression or deletion of GSK-3 present behavioral and cognitive abnormalities, positioning this protein kinase as a key signaling molecule in normal brain functioning. Furthermore, mouse models with defective GSK-3 activity display distinct structural and behavioral abnormalities, which model some aspects of different neurological and neuropsychiatric disorders. Equalizing GSK-3 activity in these mouse models by genetic or pharmacological interventions is able to rescue some of these abnormalities. Thus, GSK-3 is a relevant therapeutic target for the treatment of many brain disorders. Here, we provide an overview of how GSK-3 is regulated in physiological synaptic plasticity and how aberrant GSK-3 activity contributes to the development of dysfunctional synaptic plasticity in neuropsychiatric and neurodegenerative disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available